Literature DB >> 7527082

A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.

J P Moore1, A Trkola, B Korber, L J Boots, J A Kessler, F E McCutchan, J Mascola, D D Ho, J Robinson, A J Conley.   

Abstract

We have used virus neutralization and antibody-binding techniques to define the epitope for a human monoclonal antibody, designated 19b, within the V3 region of the gp120 surface glycoprotein of human immunodeficiency virus type 1. Unusually, the 19b epitope encompasses residues on both flanks of the V3 loop. However, 19b binding to gp120 is independent of sequences at the crown of the V3 loop, provided that they are compatible with the formation of a type II beta turn that is presumably necessary to juxtapose the antigenic residues on the V3 flanks. By comparing the V3 sequences of virus gp120s able and unable to bind 19b, we were able to define the canonical 19b epitope as -I----G--FY-T, where residues at the positions indicated by the gaps do not contribute directly to the 19b-binding site. A few conservative substitutions at the more critical residues are also compatible with 19b binding. Inspection of V3 sequences in the human immunodeficiency virus database indicated that the canonical 19b epitope is well conserved among isolates from the North American-European clade B and also among clade E isolates from Thailand and clade F isolates from Brazil. A minority of gp120s from clades A and C also possess the 19b epitope. Consistent with the theoretical predictions of its cross-clade reactivity, 19b was found to bind to gp120s from clades A, B, C, E, and F in immunoassays. However, 19b was not able to reduce the infectivity of primary viruses from clades A, E, and F that were predicted to possess the 19b epitope and only modestly reduced the infectivity of a clade C virus at low input virus concentrations. Cross-clade neutralization via V3-directed antibodies may, therefore, be difficult, even if the antibodies show broad reactivities in binding assays and the viruses theoretically possess the relevant binding site.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7527082      PMCID: PMC188555     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Passive immunization for the prevention and treatment of HIV infection.

Authors:  S Zolla-Pazner; M K Gorny
Journal:  AIDS       Date:  1992-11       Impact factor: 4.177

2.  Genetic variants of HIV-1 in Thailand.

Authors:  F E McCutchan; P A Hegerich; T P Brennan; P Phanuphak; P Singharaj; A Jugsudee; P W Berman; A M Gray; A K Fowler; D S Burke
Journal:  AIDS Res Hum Retroviruses       Date:  1992-11       Impact factor: 2.205

Review 3.  The role of the V3 loop of gp120 in HIV infection.

Authors:  J P Moore; P L Nara
Journal:  AIDS       Date:  1991       Impact factor: 4.177

4.  Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.

Authors:  M E White-Scharf; B J Potts; L M Smith; K A Sokolowski; J R Rusche; S Silver
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

5.  Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand.

Authors:  C P Pau; S Lee-Thomas; W Auwanit; J R George; C Y Ou; B S Parekh; T C Granade; D L Holloman; S Phillips; G Schochetman
Journal:  AIDS       Date:  1993-03       Impact factor: 4.177

6.  The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules.

Authors:  J P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  1993-03       Impact factor: 2.205

7.  Identification of HIV vaccine candidate peptides by screening random phage epitope libraries.

Authors:  P M Keller; B A Arnold; A R Shaw; R L Tolman; F Van Middlesworth; S Bondy; V K Rusiecki; S Koenig; S Zolla-Pazner; P Conard
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

8.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.

Authors:  C K Leonard; M W Spellman; L Riddle; R J Harris; J N Thomas; T J Gregory
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

9.  Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand.

Authors:  C Y Ou; Y Takebe; B G Weniger; C C Luo; M L Kalish; W Auwanit; S Yamazaki; H D Gayle; N L Young; G Schochetman
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

10.  Sequence analysis of the gp120 region of the env gene of Ugandan human immunodeficiency proviruses from a single individual.

Authors:  C Bruce; C Clegg; A Featherstone; J Smith; J Oram
Journal:  AIDS Res Hum Retroviruses       Date:  1993-04       Impact factor: 2.205

View more
  64 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Comparing antigenicity and immunogenicity of engineered gp120.

Authors:  Suganya Selvarajah; Bridget Puffer; Ralph Pantophlet; Mansun Law; Robert W Doms; Dennis R Burton
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

9.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

10.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.